Lantern Pharma gets USPTO Notice of Allowance for LP-284 patent
Lantern Pharma said the USPTO issued a Notice of Allowance for its LP—284 treatment patent application for aggressive B—cell lymphomas.
Lantern Pharma Inc. (NASDAQ: LTRN) said the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application N…